Drugs / Al18F-octreotide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05749289 | Dec 2022 → Dec 2028 expected | — | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Al18F-octreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05749289 ↗ |
| Modality | Diagnostic / imaging agent | “This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT” NCT05749289 ↗ |